Mutational landscape determines sensitivity
to PD-1 blockade in NSCLC: Pembrolizumab as an example
Rizvi NA, et al. Science. 2015;348:124–128.
Molecular smoking signature
Mutational burden
0
4
8
12
16
20
24
0
50
100
0
4
8
12
16
20
24
0
50
100
Percent progression-free
High nonsynonymous burden
Low nonsynonymous burden
Months
Percent progression-free
Months
Transversion high
Transversion low
Beyond the histology
